Evidence mapPaperPMID 32825652Full record

ArticlePathogens (Basel, Switzerland)2020

In Vitro Effect of Pitavastatin and Its Synergistic Activity with Isavuconazole against

Hye Jee Hahn, Jose Ignacio Escrig, Brian Shing, Anjan Debnath

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Expert review of anti-infective therapy · 2021
    Pooled it
  3. Anti-Acanthamoeba metallopharmaceuticals: Amoebicidal activity and synergistic effect of copper(II) coordination compound.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024
    Article
  4. Miconazole-like Scaffold is a Promising Lead forJournal of medicinal chemistry · 2023
    Article
  5. Emerging treatments in fungal keratitis.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hye Jee HahnCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093, USA.
Jose Ignacio EscrigCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093, USA.
Brian ShingCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093, USA.ORCID 0000-0002-5579-8940
Anjan DebnathCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093, USA.ORCID 0000-0001-9294-3927
University of California San Diego · US

Funding

NCATS NIH HHS KL2 TR001444NIAID NIH HHS R21 AI146460NIH HHS 1KL2TR001444, R21AI141210, R21AI133394, 1R21AI146460
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AcanthamoebaAcanthamoeba keratitisCYP51 inhibitorfree-living amebastatin

Identifiers

PMID32825652
PMCPMC7559540
OpenAlexW3081195642

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.